Skip to main content

Table 2 ORRs (RECIST) in patients positive for RET biomarkers

From: A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

Clinical study Objective responses, n/N (%)
RETrearrangement RETamplification LowRETgene copy number gain RET expression
Van Comp Van Comp Van Comp Van Comp
ZODIAC + ZEAL 0/1 1/2 1/6 1/7 2/14 2/14 5/16 3/24
ZEPHYR 0/2 0/1 0/2 0/3 0/19 0/5 0/18 0/10
ZEST 0/0 0/1 0/4 0/2 2/8 1/14 2/12 3/10
Overall 0/3 (0.0) 1/4 (25.0) 1/12 (8.3) 1/12 (8.3) 4/41 (9.8) 3/33 (9.1) 7/46 (15.2) 6/44 (13.6)